GSK Kicks Off Two Large Outcomes Trials In A Competitive CKD Category
The company initiated a Phase III development program for the oral HIF-PH inhibitor daprodustat as a treatment for anemia associated with chronic kidney disease. Two trials will enroll 7,500 patients.
You may also be interested in...
The treatment landscape in renal anemia is set for major changes over the next few years as a novel class of drugs approaches the market. A new report from Biomedtracker looks at the major players battling it out in the clinic.
The race to market for HIF-PH inhibitors to treat anemia associated with chronic kidney disease is highly competitive and will be complicated by the expected launch of biosimilar erythropoiesis-stimulating agents.
Management highlighted pipeline drugs in respiratory disease, HIV, immuno-oncology and vaccines, but a lot of the drugs in development are early- to mid-stage where the success rate remains uncertain. The meeting isn’t likely to change investor sentiment in the near-term.